cells

Prostate Cancer Clinical Trials

Castration-Resistant Prostate Cancer (ARC-6)

Overview

A Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant-based combination therapy in participants with metastatic castrate resistant prostate cancer.

Key Eligibility Criteria

  • Metastatic castrate-resistant prostate cancer while on anti-androgen treatment with castrate levels of testosterone (≤1.7 nmol/L or 50 ng/dL)
  • Naive to any prior treatment with immune checkpoint blockade therapy

ARC-6 Clinical Trial Locations

clinicaltrials.gov

arrow